<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38172612</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>03</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>HMGB1 mediates microbiome-immune axis dysregulation underlying reduced neutralization capacity in obesity-related post-acute sequelae of SARS-CoV-2.</ArticleTitle><Pagination><StartPage>355</StartPage><MedlinePgn>355</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">355</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-50027-1</ELocationID><Abstract><AbstractText>While obesity is a risk factor for post-acute sequelae of SARS-CoV-2 infection (PASC, "long-COVID"), the mechanism(s) underlying this phenomenon remains poorly understood. To address this gap in knowledge, we performed a 6-week longitudinal study to examine immune activity and gut microbiome dysbiosis in post-acute stage patients recovering from SARS-CoV-2 infection. Self-reported symptom frequencies and blood samples were collected weekly, with plasma assessed by ELISA and Luminex for multiple biomarkers and immune cell profiling. DNA from stool samples were collected at the early stage of recovery for baseline assessments of gut microbial composition and diversity using 16S-based metagenomic sequencing. Multiple regression analyses revealed obesity-related PASC linked to a sustained proinflammatory immune profile and reduced adaptive immunity, corresponding with reduced gut microbial diversity. In particular, enhanced signaling of the high mobility group box 1 (HMGB1) protein was found to associate with this dysregulation, with its upregulated levels in plasma associated with significantly impaired viral neutralization that was exacerbated with obesity. These findings implicate HMGB1 as a candidate biomarker of PASC, with potential applications for risk assessment and targeted therapies.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Rubas</LastName><ForeName>Noelle C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Anatomy, and Physiology, University of Hawai'i at M&#x101;noa, Honolulu, HI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deparment of Molecular Biosciences and Bioengineering, University of Hawai'i at M&#x101;noa, Honolulu, HI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Peres</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Anatomy, and Physiology, University of Hawai'i at M&#x101;noa, Honolulu, HI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunihiro</LastName><ForeName>Braden P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Anatomy, and Physiology, University of Hawai'i at M&#x101;noa, Honolulu, HI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allan</LastName><ForeName>Nina P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Anatomy, and Physiology, University of Hawai'i at M&#x101;noa, Honolulu, HI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phankitnirundorn</LastName><ForeName>Krit</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Anatomy, and Physiology, University of Hawai'i at M&#x101;noa, Honolulu, HI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wells</LastName><ForeName>Riley K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Anatomy, and Physiology, University of Hawai'i at M&#x101;noa, Honolulu, HI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deparment of Molecular Biosciences and Bioengineering, University of Hawai'i at M&#x101;noa, Honolulu, HI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCracken</LastName><ForeName>Trevor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Anatomy, and Physiology, University of Hawai'i at M&#x101;noa, Honolulu, HI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Rosa H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Anatomy, and Physiology, University of Hawai'i at M&#x101;noa, Honolulu, HI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umeda</LastName><ForeName>Lesley</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Anatomy, and Physiology, University of Hawai'i at M&#x101;noa, Honolulu, HI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deparment of Molecular Biosciences and Bioengineering, University of Hawai'i at M&#x101;noa, Honolulu, HI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conching</LastName><ForeName>Andie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hawai'i Integrated Analytics, Honolulu, HI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juarez</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hawai'i Integrated Analytics, Honolulu, HI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deparment of Economics and UHERO, University of Hawai'i at M&#x101;noa, Honolulu, HI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maunakea</LastName><ForeName>Alika K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Anatomy, and Physiology, University of Hawai'i at M&#x101;noa, Honolulu, HI, USA. amaunake@hawaii.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hawai'i Integrated Analytics, Honolulu, HI, USA. amaunake@hawaii.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MD016593</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024243">HMGB1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C585491">HMGB1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Sci Rep. 2024 Mar 19;14(1):6559. doi: 10.1038/s41598-024-56011-7</RefSource><PMID Version="1">38504105</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024243" MajorTopicYN="Y">HMGB1 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064307" MajorTopicYN="Y">Microbiota</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors of this research paper declare the following potential conflicts of interest regarding patentable product associated with this study. Ruben Juarez and Alika Maunakea from HI&#x2bb;A may file a patent application related to technology described in this paper. Furthermore, Ruben Juarez and Alika Maunakea have a financial interest in HI&#x2bb;A, a company that holds the exclusive license for commercializing of this technology. The involvement of the authors in the patent and the company does not influence the objectivity, integrity, or validity of the research findings presented in this paper. All data and results have been analyzed impartially, and appropriate steps have been taken to mitigate any potential bias. This conflict of interest disclosure is made to ensure transparency and maintain the highest ethical standards in scientific research. The other authors declare no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>4</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>3</Day><Hour>23</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38172612</ArticleId><ArticleId IdType="pmc">PMC10764757</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-50027-1</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-50027-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 2022;23(2):210&#x2013;216. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Davitt E, Davitt C, Mazer MB, Areti SS, Hotchkiss RS, Remy KE. COVID-19 disease and immune dysregulation. Best Pract. Res. Clin. Haematol. 2022;35(3):101401. doi: 10.1016/j.beha.2022.101401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beha.2022.101401</ArticleId><ArticleId IdType="pmc">PMC9568269</ArticleId><ArticleId IdType="pubmed">36494149</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Q, Lau RI, Liu Q, Chan FKL, Ng SC. Post-acute COVID-19 syndrome and gut dysbiosis linger beyond 1 year after SARS-CoV-2 clearance. Gut. 2022 doi: 10.1136/gutjnl-2022-328319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2022-328319</ArticleId><ArticleId IdType="pubmed">35940857</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Mak JWY, Su Q, et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022;71(3):544&#x2013;552. doi: 10.1136/gutjnl-2021-325989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325989</ArticleId><ArticleId IdType="pubmed">35082169</ArticleId></ArticleIdList></Reference><Reference><Citation>Aminian A, Bena J, Pantalone KM, Burguera B. Association of obesity with postacute sequelae of COVID-19. Diabetes Obes. Metab. 2021;23(9):2183&#x2013;2188. doi: 10.1111/dom.14454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14454</ArticleId><ArticleId IdType="pmc">PMC8239834</ArticleId><ArticleId IdType="pubmed">34060194</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherer PE, Kirwan JP, Rosen CJ. Post-acute sequelae of COVID-19: A metabolic perspective. ELife. 2022;11:e78200. doi: 10.7554/eLife.78200.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.78200</ArticleId><ArticleId IdType="pmc">PMC8942467</ArticleId><ArticleId IdType="pubmed">35318939</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce JD, Shen Q, Cintron SA, Hiebert JB. Post-COVID-19 syndrome. Nurs. Res. 2022;71(2):164&#x2013;174. doi: 10.1097/NNR.0000000000000565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NNR.0000000000000565</ArticleId><ArticleId IdType="pubmed">34653099</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Post-COVID Conditions. Centers for Disease Control and Prevention. Published September 1, 2022. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. Accessed 12 Dec 2022.</Citation></Reference><Reference><Citation>Post-acute sequelae of COVID-19 (PASC): A meta-narrative review of pathophysiology, prevalence, and management. https://www-ncbi-nlm-nih-gov.eres.library.manoa.hawaii.edu/pmc/articles/PMC8977184/. Accessed 22 Feb 2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8977184</ArticleId><ArticleId IdType="pubmed">35402784</ArticleId></ArticleIdList></Reference><Reference><Citation>Vimercati L, De Maria L, Quarato M, et al. Association between long COVID and overweight/obesity. J. Clin. Med. 2021;10(18):4143. doi: 10.3390/jcm10184143.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10184143</ArticleId><ArticleId IdType="pmc">PMC8469321</ArticleId><ArticleId IdType="pubmed">34575251</ArticleId></ArticleIdList></Reference><Reference><Citation>Extracellular HMGB1: A therapeutic target in severe pulmonary inflammation including COVID-19? Mol. Med. (2023). 10.1186/s10020-020-00172-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7203545</ArticleId><ArticleId IdType="pubmed">32380958</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Huang Y, Quan J, et al. HMGB1 as a potential biomarker and therapeutic target for severe COVID-19. Heliyon. 2020;6(12):e05672. doi: 10.1016/j.heliyon.2020.e05672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2020.e05672</ArticleId><ArticleId IdType="pmc">PMC7720697</ArticleId><ArticleId IdType="pubmed">33313438</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjendra Y, Al Mana AF, Espejo AP, et al. Predicting disease severity and outcome in COVID-19 patients: A review of multiple biomarkers. Arch. Pathol. Lab. Med. 2020;144(12):1465&#x2013;1474. doi: 10.5858/arpa.2020-0471-SA.</Citation><ArticleIdList><ArticleId IdType="doi">10.5858/arpa.2020-0471-SA</ArticleId><ArticleId IdType="pubmed">32818235</ArticleId></ArticleIdList></Reference><Reference><Citation>Karadag F, Kirdar S, Karul AB, Ceylan E. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur. J. Intern. Med. 2008;19(2):104&#x2013;108. doi: 10.1016/j.ejim.2007.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2007.04.026</ArticleId><ArticleId IdType="pubmed">18249305</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins MC, Lima Faleiro L, Fonseca A. Relationship between leptin and body mass and metabolic syndrome in an adult population. Rev. Portugues. Cardiol. 2012;31(11):711&#x2013;719. doi: 10.1016/j.repce.2012.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.repce.2012.09.008</ArticleId><ArticleId IdType="pubmed">23040870</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YH, Choi BH, Cheon HG, Do MS. B cell activation factor (BAFF) is a novel adipokine that links obesity and inflammation. Exp. Mol. Med. 2009;41(3):208&#x2013;216. doi: 10.3858/emm.2009.41.3.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3858/emm.2009.41.3.024</ArticleId><ArticleId IdType="pmc">PMC2679246</ArticleId><ArticleId IdType="pubmed">19293640</ArticleId></ArticleIdList></Reference><Reference><Citation>Do MS, Jeong HS, Choi BH, et al. Inflammatory gene expression patterns revealed by DNA microarray analysis in TNF-&#x3b1;-treated SGBS human adipocytes. Yonsei Med. J. 2006;47(5):729&#x2013;736. doi: 10.3349/ymj.2006.47.5.729.</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2006.47.5.729</ArticleId><ArticleId IdType="pmc">PMC2687760</ArticleId><ArticleId IdType="pubmed">17066518</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Zhang L, Zhang S, et al. HMGB1, an innate alarmin, plays a critical role in chronic inflammation of adipose tissue in obesity. Mol. Cell. Endocrinol. 2017;454:103&#x2013;111. doi: 10.1016/j.mce.2017.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2017.06.012</ArticleId><ArticleId IdType="pubmed">28619625</ArticleId></ArticleIdList></Reference><Reference><Citation>Holms RD. Long COVID (PASC) is maintained by a self-sustaining pro-inflammatory TLR4/RAGE-loop of S100A8/A9 &gt; TLR4/RAGE signalling, inducing chronic expression of IL-1b, IL-6 and TNFa: Anti-inflammatory ezrin peptides as potential therapy. Immuno. 2022;2(3):512&#x2013;533. doi: 10.3390/immuno2030033.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/immuno2030033</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim ZA, Armour CL, Phipps S, Sukkar MB. RAGE and TLRs: Relatives, friends or neighbours? Mol. Immunol. 2013;56(4):739&#x2013;744. doi: 10.1016/j.molimm.2013.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2013.07.008</ArticleId><ArticleId IdType="pubmed">23954397</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int. J. Obes. 1998;22(12):1145&#x2013;1158. doi: 10.1038/sj.ijo.0800770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijo.0800770</ArticleId><ArticleId IdType="pubmed">9877249</ArticleId></ArticleIdList></Reference><Reference><Citation>Fantuzzi G. Adipose tissue, adipokines, and inflammation. J. Allergy Clin. Immunol. 2005;115(5):911&#x2013;919. doi: 10.1016/j.jaci.2005.02.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2005.02.023</ArticleId><ArticleId IdType="pubmed">15867843</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra KP, Singh AK, Singh SB. Hyperinflammation and immune response generation in COVID-19. Neuroimmunomodulation. 2020;27(2):80&#x2013;86. doi: 10.1159/000513198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000513198</ArticleId><ArticleId IdType="pmc">PMC7801965</ArticleId><ArticleId IdType="pubmed">33341814</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong RSY. Inflammation in COVID-19: From pathogenesis to treatment. Int. J. Clin. Exp. Pathol. 2021;14(7):831&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8339720</ArticleId><ArticleId IdType="pubmed">34367415</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagerty SL, Hutchison KE, Lowry CA, Bryan AD. An empirically derived method for measuring human gut microbiome alpha diversity: Demonstrated utility in predicting health-related outcomes among a human clinical sample. PLOS ONE. 2020;15(3):e0229204. doi: 10.1371/journal.pone.0229204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0229204</ArticleId><ArticleId IdType="pmc">PMC7051054</ArticleId><ArticleId IdType="pubmed">32119675</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner BD, Grunwald GK, Zerbe GO, et al. On the use of diversity measures in longitudinal sequencing studies of microbial communities. Front. Microbiol. 2018;9:1037. doi: 10.3389/fmicb.2018.01037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.01037</ArticleId><ArticleId IdType="pmc">PMC5972327</ArticleId><ArticleId IdType="pubmed">29872428</ArticleId></ArticleIdList></Reference><Reference><Citation>Song X, Dai D, He X, et al. Growth factor FGF2 cooperates with interleukin-17 to repair intestinal epithelial damage. Immunity. 2015;43(3):488&#x2013;501. doi: 10.1016/j.immuni.2015.06.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2015.06.024</ArticleId><ArticleId IdType="pubmed">26320657</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng J, Ni Q, Sun W, Li L, Feng X. The links between gut microbiota and obesity and obesity related diseases. Biomed. Pharmacother. 2022;147:112678. doi: 10.1016/j.biopha.2022.112678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.112678</ArticleId><ArticleId IdType="pubmed">35134709</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia: PMC. https://www-ncbi-nlm-nih-gov.eres.library.manoa.hawaii.edu/pmc/articles/PMC9626559/. Accessed March 6, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9626559</ArticleId><ArticleId IdType="pubmed">36319618</ArticleId></ArticleIdList></Reference><Reference><Citation>Arboleya S, Watkins C, Stanton C, Ross RP. Gut bifidobacteria populations in human health and aging. Front. Microbiol. 2016 doi: 10.3389/fmicb.2016.01204.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2016.01204</ArticleId><ArticleId IdType="pmc">PMC4990546</ArticleId><ArticleId IdType="pubmed">27594848</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazan S, Stollman N, Bozkurt HS, et al. Lost microbes of COVID-19: Bifidobacterium, Faecalibacterium depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity. BMJ Open Gastroenterol. 2022;9(1):e000871. doi: 10.1136/bmjgast-2022-000871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgast-2022-000871</ArticleId><ArticleId IdType="pmc">PMC9051551</ArticleId><ArticleId IdType="pubmed">35483736</ArticleId></ArticleIdList></Reference><Reference><Citation>Splichal I, Donovan SM, Kindlova Z, et al. Release of HMGB1 and toll-like receptors 2, 4, and 9 signaling are modulated by Bifidobacterium animalis subsp. lactis BB-12 and salmonella typhimurium in a gnotobiotic piglet model of preterm infants. Int. J. Mol. Sci. 2023;24(3):2329. doi: 10.3390/ijms24032329.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24032329</ArticleId><ArticleId IdType="pmc">PMC9916534</ArticleId><ArticleId IdType="pubmed">36768650</ArticleId></ArticleIdList></Reference><Reference><Citation>Christiaen SEA, O&#x2019;Connell Motherway M, Bottacini F, et al. Autoinducer-2 plays a crucial role in gut colonization and probiotic functionality of Bifidobacterium breve UCC2003. PLoS ONE. 2014;9(5):e98111. doi: 10.1371/journal.pone.0098111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0098111</ArticleId><ArticleId IdType="pmc">PMC4037206</ArticleId><ArticleId IdType="pubmed">24871429</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang FC, Pei JX, Zhu J, et al. Overexpression of HMGB1 A-box reduced lipopolysaccharide-induced intestinal inflammation via HMGB1/TLR4 signaling in vitro. World J. Gastroenterol. 2015;21(25):7764&#x2013;7776. doi: 10.3748/wjg.v21.i25.7764.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v21.i25.7764</ArticleId><ArticleId IdType="pmc">PMC4491963</ArticleId><ArticleId IdType="pubmed">26167076</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedrich K, Sommer M, Strobel S, et al. Perturbation of the monocyte compartment in human obesity. Front. Immunol. 2019;10:1874. doi: 10.3389/fimmu.2019.01874.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01874</ArticleId><ArticleId IdType="pmc">PMC6694869</ArticleId><ArticleId IdType="pubmed">31440251</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala E, Kuka M. The suppressive attitude of inflammatory monocytes in antiviral antibody responses. Viral Immunol. 2020;33(4):327&#x2013;333. doi: 10.1089/vim.2019.0132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2019.0132</ArticleId><ArticleId IdType="pmc">PMC7247028</ArticleId><ArticleId IdType="pubmed">32027238</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK, Francisco EB, Yogendra R, et al. Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection. Front. Immunol. 2022 doi: 10.3389/fimmu.2021.746021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.746021</ArticleId><ArticleId IdType="pmc">PMC8784688</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Benna S. Association of high level gene expression of ACE2 in adipose tissue with mortality of COVID-19 infection in obese patients. Obes. Med. 2020;19:100283. doi: 10.1016/j.obmed.2020.100283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.obmed.2020.100283</ArticleId><ArticleId IdType="pmc">PMC7368415</ArticleId><ArticleId IdType="pubmed">32835126</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiappalupi S, Salvadori L, Donato R, Riuzzi F, Sorci G. Hyperactivated RAGE in comorbidities as a risk factor for severe COVID-19-the role of RAGE-RAS crosstalk. Biomolecules. 2021;11(6):876. doi: 10.3390/biom11060876.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11060876</ArticleId><ArticleId IdType="pmc">PMC8231494</ArticleId><ArticleId IdType="pubmed">34204735</ArticleId></ArticleIdList></Reference><Reference><Citation>Faizo AA, Qashqari FS, El-Kafrawy SA, et al. A potential association between obesity and reduced effectiveness of COVID-19 vaccine-induced neutralizing humoral immunity. J. Med. Virol. 2022 doi: 10.1002/jmv.28130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28130</ArticleId><ArticleId IdType="pmc">PMC9539352</ArticleId><ArticleId IdType="pubmed">36068377</ArticleId></ArticleIdList></Reference><Reference><Citation>Frasca D, Reidy L, Romero M, et al. The majority of SARS-CoV-2-specific antibodies in COVID-19 patients with obesity are autoimmune and not neutralizing. Int. J. Obes. 2022;46(2):427&#x2013;432. doi: 10.1038/s41366-021-01016-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41366-021-01016-9</ArticleId><ArticleId IdType="pmc">PMC8572364</ArticleId><ArticleId IdType="pubmed">34744161</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SE, Feng A, Meng W, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat. Commun. 2021;12(1):5417. doi: 10.1038/s41467-021-25509-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25509-3</ArticleId><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Relative reduction of biological and phylogenetic diversity of the oral microbiota of diabetes and pre-diabetes patients: PubMed. https://pubmed-ncbi-nlm-nih-gov.eres.library.manoa.hawaii.edu/30625362/. Accessed 16 Dec 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">30625362</ArticleId></ArticleIdList></Reference><Reference><Citation>Karabudak S, Ari O, Durmaz B, et al. Analysis of the effect of smoking on the buccal microbiome using next-generation sequencing technology. J. Med. Microbiol. 2019;68(8):1148&#x2013;1158. doi: 10.1099/jmm.0.001003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jmm.0.001003</ArticleId><ArticleId IdType="pubmed">31199220</ArticleId></ArticleIdList></Reference><Reference><Citation>(PDF) lavaan: An R package for structural equation modeling. https://www.researchgate.net/publication/260350824_lavaan_An_R_Package_for_Structural_Equation_Modeling. Accessed 5 Sept 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>